Opportunities for control of meningococcal disease in the United States

Area of Science:

• Public Health
• Epidemiology
• Vaccinology

Background:

• Meningococcal disease, caused by Neisseria meningitidis, presents with relatively low incidence in the US, primarily involving serogroups Y, C, and B.
• While often sporadic, outbreaks occur, disproportionately affecting pediatric populations, yet the majority of cases are in individuals aged 15 and older.
• Current control challenges stem from the lack of a broadly applicable vaccine for sporadic cases across diverse age demographics.

Purpose of the Study:

• To review the epidemiology of meningococcal disease in the United States.
• To discuss the limitations of existing vaccines and the potential impact of newer conjugate vaccines.

Main Methods:

• Literature review of meningococcal disease epidemiology and vaccine efficacy.
• Analysis of current vaccination recommendations and challenges.

Main Results:

• Serogroups Y, C, and B are most prevalent in the US.
• The quadrivalent A/C/Y/W-135 polysaccharide vaccine has limited efficacy in young children and is reserved for high-risk groups or outbreak control.
• New conjugate vaccines have demonstrated success in reducing endemic disease internationally.

Conclusions:

• The absence of a universally effective vaccine hinders control of sporadic meningococcal disease in the US.
• Conjugate meningococcal vaccines are anticipated to significantly decrease the burden of disease in the United States.